Evans John M.'s Form 4 filing
Beam Therapeutics Inc. (BEAM) · filed Jul 1, 2026
- Accession no.
- 0001193125-26-292526
- Filed
- Jul 1, 2026, 4:05 PM ET
- Trade date
- Jun 29-30, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.75M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Evans John M.CIK 0001786304 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +18,663 | $0.67 | +$12,504.21 | 1,065,868 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseAcquired | +6,337 | $1.03 | +$6,527.11 | 1,072,205 | Direct | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −13,421 | $35.13F2 | −$471,528.05 | 1,058,784 | Direct | |
| Jun 29, 2026 | Common Stock | SSaleDisposed | −11,579 | $35.91F3 | −$415,823.89 | 1,047,205 | Direct | |
| Jun 30, 2026 | Common Stock | MOption exerciseAcquired | +25,000 | $1.03 | +$25,750 | 1,072,205 | Direct | |
| Jun 30, 2026 | Common Stock | SSaleDisposed | −23,100 | $34.26F4 | −$791,482.23 | 1,049,105 | Direct | |
| Jun 30, 2026 | Common Stock | SSaleDisposed | −1,900 | $34.84F5 | −$66,203.03 | 1,047,205 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −18,663 | $0.00 | $0 | 9 | Direct | |
| Jun 29, 2026 | Common Stock | MOption exerciseDisposed | −6,337 | $0.00 | $0 | 230,804 | Direct | |
| Jun 30, 2026 | Common Stock | MOption exerciseDisposed | −25,000 | $0.00 | $0 | 205,804 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.55 to $35.50, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.60 to $36.18, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $33.80 to $34.71, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $34.83 to $34.85, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Referenced by the price of 1 transaction in Table I.